Clinical Trial

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-08-20
Trial Details
NCT Number NCT06917664
Lead Sponsor China National Center for Cardiovascular Diseases
Collaborators: Chinese Academy of Medical Sciences, Fuwai Hospital, Chinese Academy of Medical Sciences
Conditions Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor
Enrollment 220 participants
Start Date 2025-06-05
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-27